BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma. ・Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable ...

BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma ...

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage ...

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...

BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price ...

BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even ...

View BioLineRX Ltd. Sponsored ADR BLRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination ...

BioLine RX Ltd. ADR Annual stock financials by MarketWatch. View the latest BLRX financial statements, income statements and financial ratios.